Key facts
- This page summarizes Michael P. Stansky's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2026, 16:42.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.52 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Footnote F3
The securities reported herein are owned by Skyview Investments LLC. Mr. Stansky serves as managing member of Skyview Investments LLC (and in such capacity may be deemed to beneficially own the securities reported herein). Voting and dispositive power over the securities owned by Skyview Investments LLC is exercised in his capacity as managing member.